Chemed/$CHE
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Chemed
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Ticker
$CHE
Sector
Primary listing
NYSE
Industry
Health Care Providers & Services
Headquarters
Employees
15,695
ISIN
US16359R1032
Website
Chemed Metrics
BasicAdvanced
$6.9B
22.96
$20.53
0.59
$2.00
0.42%
Price and volume
Market cap
$6.9B
Beta
0.59
52-week high
$623.61
52-week low
$471.24
Average daily volume
163K
Dividend rate
$2.00
Financial strength
Current ratio
1.729
Quick ratio
1.582
Long term debt to equity
8.638
Total debt to equity
12.275
Dividend payout ratio (TTM)
9.19%
Interest coverage (TTM)
231.21%
Profitability
EBITDA (TTM)
453.659
Gross margin (TTM)
34.82%
Net profit margin (TTM)
12.40%
Operating margin (TTM)
15.64%
Effective tax rate (TTM)
24.82%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
14.09%
Return on equity (TTM)
26.11%
Valuation
Price to earnings (TTM)
22.958
Price to revenue (TTM)
2.821
Price to book
5.83
Price to tangible book (TTM)
16.22
Price to free cash flow (TTM)
22.286
Free cash flow yield (TTM)
4.49%
Free cash flow per share (TTM)
2,114.50%
Dividend yield (TTM)
0.42%
Forward dividend yield
0.42%
Growth
Revenue change (TTM)
8.52%
Earnings per share change (TTM)
10.48%
3-year revenue growth (CAGR)
5.12%
10-year revenue growth (CAGR)
5.37%
3-year earnings per share growth (CAGR)
6.34%
10-year earnings per share growth (CAGR)
13.35%
3-year dividend per share growth (CAGR)
10.19%
10-year dividend per share growth (CAGR)
8.25%
What the Analysts think about Chemed
Analyst ratings (Buy, Hold, Sell) for Chemed stock.
Bulls say / Bears say
Chemed's VITAS Healthcare segment reported a 17.3% increase in net patient revenue to $391.4 million in Q3 2024, driven by a 15.5% rise in Average Daily Census and a 6.3% increase in admissions. (tradingview.com)
The company authorized an additional $300 million for stock repurchases, indicating confidence in its financial position and commitment to returning value to shareholders. (investing.com)
Analysts forecast Chemed's revenue to grow by 5.9% to $2.64 billion in 2025, with earnings per share expected to rise by 6.1% to $22.48, reflecting positive growth expectations. (simplywall.st)
Chemed's Roto-Rooter segment experienced a 6.9% decline in revenue to $214.8 million in Q3 2024, with net income decreasing by 18.9%, indicating challenges in this business line. (tradingview.com)
The company's stock price has shown volatility, with a 5.8% decline in the first quarter of 2025, which may concern investors about short-term performance. (tradingview.com)
Analyst ratings have been mixed, with StockNews.com downgrading Chemed from a 'buy' to a 'hold' rating, suggesting potential concerns about future performance. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Chemed Financial Performance
Revenues and expenses
Chemed Earnings Performance
Company profitability
Chemed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Chemed stock?
Chemed (CHE) has a market cap of $6.9B as of July 04, 2025.
What is the P/E ratio for Chemed stock?
The price to earnings (P/E) ratio for Chemed (CHE) stock is 22.96 as of July 04, 2025.
Does Chemed stock pay dividends?
Yes, the Chemed (CHE) stock pays dividends to shareholders. As of July 04, 2025, the dividend rate is $2 and the yield is 0.42%. Chemed has a payout ratio of 9.19% on a trailing twelve-month basis.
When is the next Chemed dividend payment date?
The next Chemed (CHE) dividend payment date is unconfirmed.
What is the beta indicator for Chemed?
Chemed (CHE) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.